# Transcriptomic Analysis of BRCA1-Driven Gynecological 
# Malignancies Modulated by Nulliparity
## Full Project Report

### 1. Introduction
*(# Transcriptomic Analysis of BRCA1-Driven Gynecological Malignancies Modulated by Nulliparity

## Project Abstract
This repository hosts a computational pipeline investigating how reproductive history alters the genomic landscape of gynecological tumors in high-risk genetic cohorts. Specifically, we explore how nulliparity acts as a hormonal and proliferative modifier that shifts or accelerates gene expression within BRCA1-deficient ovarian and endometrial tumors.

---

## Literature Review & Theoretical Framework
### I. The Genomic Underpinning: BRCA1 Loss of Function
The Breast Cancer Susceptibility Gene 1 (BRCA1), localized to chromosome 17q21, encodes a nuclear phosphoprotein vital for maintaining genomic integrity through high-fidelity Homologous Recombination Repair (HRR) of double-strand DNA breaks. Individuals carrying an inherited germline BRCA1 mutation are highly predisposed to malignant transformation following somatic Loss of Heterozygosity (LOH). Deprived of HRR, cells default to error-prone pathways such as Non-Homologous End Joining (NHEJ), resulting in accelerated genomic instability and structural chromosomal aberrations.

---

### II. The Ovarian Paradigm: Incessant Ovulation and the Nulliparity Risk Multiplier
While BRCA1 mutations are systemic, phenotypic oncogenesis is heavily concentrated within gynecological tissues. Cross-national epidemiological analyses by Ali et al. (2023) demonstrate that nulliparity independently elevates ovarian cancer risk by 24% compared to parous populations.
This finding strongly correlates with the Incessant Ovulation Hypothesis. Every ovulatory cycle inflicts recurring physical trauma and localized inflammatory stress upon the ovarian surface epithelium and distal fallopian tube fimbriae. Full-term pregnancies and lactation suppress ovulation, granting these tissues prolonged periods of rest and cellular repair. In nulliparous individuals, the absence of these protective pauses induces chronic proliferative stress. When this baseline risk increase intersects with a compromised BRCA1 background, the inability to repair replication errors accrued during relentless tissue remodeling drives rapid progression toward High-Grade Serous Ovarian Carcinomas (HGSOC).

---

### III. The Endometrial Axis: Unopposed Estrogen Signaling and Quantified BRCA1 Risk
Large multicenter cohort evaluations by de Jonge et al. (2021) provide precise quantification of endometrial cancer risk in BRCA1/2 carriers. BRCA1 carriers face a 3.5-fold increased overall endometrial cancer risk (Standardized Incidence Ratio, SIR = 3.51) relative to the general population — significantly higher than the 1.7-fold risk observed in BRCA2 carriers (SIR = 1.70). This differential is even more pronounced for aggressive histotypes: BRCA1 carriers carry a 12.6-fold elevated risk (SIR = 12.64) for p53-abnormal, serous-like endometrial carcinomas, compared to a 5.1-fold risk (SIR = 5.11) in BRCA2 carriers. These figures establish BRCA1 as the dominant germline driver of aggressive endometrial malignancy.
| Metric | BRCA1 Carriers | BRCA2 Carriers |
| :--- | :--- | :--- |
| **Overall Endometrial Cancer Risk** | `SIR = 3.51` (3.5-fold) | `SIR = 1.70` (1.7-fold) |
| **p53-abnormal, Serous-like Carcinomas** | `SIR = 12.64` (12.6-fold) | `SIR = 5.11` (5.1-fold) |

As synthesized by Sorouri et al. (2023), classical endometrioid endometrial oncogenesis is driven by elevated, unopposed estrogen. In nulliparous women, the physiological milieu lacks the dominant, protective progesterone surges characteristic of pregnancy, exposing the endometrium to chronic, unchecked estrogenic proliferation. This compounding of hormonal vulnerability upon an already compromised BRCA1 repair background creates a dual-hit oncogenic environment — genomic instability layered over sustained mitogenic signaling. Sorouri et al. (2023) further argue that this elevated cumulative risk creates a strong clinical case for risk-reducing hysterectomy (rr-hysterectomy) concurrently with risk-reducing bilateral salpingo-oophorectomy (rr-BSO) in BRCA1 carriers.

---

### IV. Identified Knowledge Gap & Computational Objective
While the existing literature presents well-defined individual pipelines for germline genomic risk (BRCA1 status) and epidemiological risk (nulliparity), their transcriptomic intersection remains undefined. Large-scale sequencing projects such as The Cancer Genome Atlas (TCGA) contain rich multi-omic data layers but are rarely stratified concurrently by parity metrics, leaving the question of how nulliparity modulates gene expression within BRCA1-deficient tumors largely unexplored.
The objective of this study is therefore to leverage publicly available TCGA transcriptomic data to characterize differential gene expression patterns in BRCA1-deficient ovarian and endometrial tumors, stratified by parity status, in order to identify molecular signatures through which nulliparity accelerates or modifies gynecological oncogenesis in high-risk populations.

---

## References

* **Ali, A. T., Al-Ani, O., & Al-Ani, F. (2023).** Epidemiology and risk factors for ovarian cancer. *Menopause Review/Przegląd Menopauzalny*, 22(2), 93–104.
* **de Jonge, M. M., de Kroon, C. D., Jenner, D. J., Oosting, J., De Hullu, J. A., Mourits, M. J. E., ... & van Asperen, C. (2021).** Endometrial cancer risk in women with germline BRCA1 or BRCA2 mutations. *Journal of the National Cancer Institute*, 113(9), 1203–1211.
* **Sorouri, K., Lynce, F., Feltmate, C. M., Davis, M. R., Muto, M. G., Konstantinopoulos, P. A., ... & Bychkovsky, B. L. (2023).** Endometrial cancer risk among germline BRCA1/2 pathogenic variant carriers: review of our current understanding and next steps. *JCO Precision Oncology*, 7, e2300290.
)*

### 2. Materials & Methods
*(We fill this in phase by phase as we work)*
#### 2.1 Sequence Retrieval
The reference mRNA sequence of BRCA1 (accession: NM_007294.4) 
and its corresponding protein sequence (accession: NP_009225.1) 
were retrieved from the NCBI nucleotide and protein databases 
respectively in FASTA format and stored locally for downstream 
analysis.

### 3. Results
*(Figures, outputs, and findings added after each analysis)*

### 4. Discussion
*(Written after results are complete)*

### 5. Conclusion
*(Written last)*

### 6. References
*(Already compiled in README)*